<DOC>
	<DOCNO>NCT01216072</DOCNO>
	<brief_summary>The purpose study evaluate change patient-reported outcome , physician assessment change well safety tolerability patient Relapsing Forms Multiple Sclerosis previous Disease Modifying Therapy ( DMT ) randomize one two treatment arm : fingolimod vs. standard care DMT .</brief_summary>
	<brief_title>A 6-month , Randomized , Open-label , Patient OutComes , Safety Tolerability Study Fingolimod ( FTY720 ) 0.5 mg/Day vs. Comparator Patients With Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Relapsing form MS Expanded Disability Status Scale ( EDSS ) 05.5 Continuous treatment MS DMT minimum 6 month Fingolimod naive Immune system diseases MS Active macular edema History select prior infection criteria immunization History select immune system treatment and/or medication Selected cardiovascular , pulmonary , hepatic condition Selected abnormal laboratory value Pregnant nursing woman Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Relapsing Forms Multiple Sclerosis</keyword>
	<keyword>Disease Modifying Therapy</keyword>
	<keyword>fingolimod</keyword>
	<keyword>Patient Reported Outcomes</keyword>
</DOC>